NO20004281L - 6,9-disubstituerte 2-[trans-(4-aminocykloheksyl)amino]puriner, farmasoytisk preparat inneholdende disse, og anvendelse derav for fremstilling av et medikament - Google Patents
6,9-disubstituerte 2-[trans-(4-aminocykloheksyl)amino]puriner, farmasoytisk preparat inneholdende disse, og anvendelse derav for fremstilling av et medikamentInfo
- Publication number
- NO20004281L NO20004281L NO20004281A NO20004281A NO20004281L NO 20004281 L NO20004281 L NO 20004281L NO 20004281 A NO20004281 A NO 20004281A NO 20004281 A NO20004281 A NO 20004281A NO 20004281 L NO20004281 L NO 20004281L
- Authority
- NO
- Norway
- Prior art keywords
- present
- provides
- group
- alkyl
- formula
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 6,9-disubstituted 2- [trans- (4-aminocyclohexyl) amino] purines Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108091007914 CDKs Proteins 0.000 abstract 1
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000006369 cell cycle progression Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer nye forbindelser av formel (I). hvori R er valgt fra gruppen bestående av R, RNH-, eller HN-R- hvori Rer valgt fra gruppen bestående av C^-C,-alkyl og formel (II). hvori Z er valgt fra gruppen bestående av fenyl, heterosyklus og sykloalkyl, hver Rer uavhengig hydrogen eller C-C-alkyl, og n er et helt tall på 1-8;. hvori hver C-C-alkyl og Z eventuelt er substituert med 1 til 3 substituenter som kan være like eller forskjellige, valgt fra gruppen bestående av Hal, OH og Cj-C-alkyl; Rer q-C-alkylen; og R,, er valgt fra gruppen bestående av syklopentyl og isopropyl, og farmasøyt-isk akseptable salter, optiske isbmerer • og hydrater derav. I tillegg tilveiebringer foreliggende oppfinnelse en metode for inhibering av cellesyklus-progresjon. Mer spesifikt tilveiebringer foreliggende oppfinnelse en metode for inhibering av syklinav-hengige kinaser, i særdeleshet cdk-2. Foreliggende oppfinnelse tilveiebringer også en metode for forhindring av apoptose i neuronalceller og en metode for inhibering av utviklingen a-v neo-plasmer. I tillegg tilveiebringer foreliggende oppfinnelse et preparat, omfattende en målbar mengde av efor-. bindelse av formel (I) i blanding eller på annen måte i assosiasjon med en inert bærer. Foreliggende oppfinnelse tilveiebringer også et farmasøytisk preparat omfattende en effektiv inhi-berende mengde av en forbindelse av formel (I), i blanding eller på annen måte i assosiasjon med én eller flére farmasøytisk akseptable bærere eller eksipienser.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3238198A | 1998-02-26 | 1998-02-26 | |
| PCT/US1999/003451 WO1999043676A2 (en) | 1998-02-26 | 1999-02-18 | 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20004281D0 NO20004281D0 (no) | 2000-08-25 |
| NO20004281L true NO20004281L (no) | 2000-10-18 |
Family
ID=21864658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004281A NO20004281L (no) | 1998-02-26 | 2000-08-25 | 6,9-disubstituerte 2-[trans-(4-aminocykloheksyl)amino]puriner, farmasoytisk preparat inneholdende disse, og anvendelse derav for fremstilling av et medikament |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1056745B1 (no) |
| JP (1) | JP2002504553A (no) |
| KR (1) | KR100568658B1 (no) |
| CN (1) | CN1128149C (no) |
| AP (1) | AP1258A (no) |
| AR (1) | AR019822A1 (no) |
| AT (1) | ATE269332T1 (no) |
| AU (1) | AU748178B2 (no) |
| BR (1) | BR9908325A (no) |
| CA (1) | CA2320448C (no) |
| CZ (1) | CZ291604B6 (no) |
| DE (1) | DE69918062T2 (no) |
| DK (1) | DK1056745T3 (no) |
| EE (1) | EE04315B1 (no) |
| ES (1) | ES2219038T3 (no) |
| HU (1) | HUP0100931A3 (no) |
| IL (2) | IL138044A0 (no) |
| NO (1) | NO20004281L (no) |
| NZ (1) | NZ506234A (no) |
| OA (1) | OA11480A (no) |
| PL (1) | PL344021A1 (no) |
| PT (1) | PT1056745E (no) |
| RU (1) | RU2191777C2 (no) |
| SI (1) | SI1056745T1 (no) |
| SK (1) | SK12912000A3 (no) |
| TR (1) | TR200002482T2 (no) |
| TW (1) | TW541308B (no) |
| UA (1) | UA62996C2 (no) |
| WO (1) | WO1999043676A2 (no) |
| ZA (1) | ZA991548B (no) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6969720B2 (en) | 1999-03-17 | 2005-11-29 | Amr Technology, Inc. | Biaryl substituted purine derivatives as potent antiproliferative agents |
| US6627633B2 (en) * | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
| US20030187261A1 (en) * | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| FR2806626B1 (fr) * | 2000-03-22 | 2003-11-28 | Centre Nat Rech Scient | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues |
| JP2004501083A (ja) | 2000-04-18 | 2004-01-15 | アゴーロン・ファーマシューティカルズ・インコーポレイテッド | プロテインキナーゼを阻害するためのピラゾール |
| JP2004505983A (ja) | 2000-08-09 | 2004-02-26 | アグーロン ファーマシューティカルズ，インコーポレイテッド | ピラゾール−チアゾール化合物、これらを含む医薬組成物、およびサイクリン依存性キナーゼの阻害のためのこれらの使用方法 |
| CA2411924A1 (en) | 2000-08-18 | 2002-02-28 | Agouron Pharmaceuticals, Inc. | Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting proteinkinases |
| ATE426603T1 (de) * | 2000-10-31 | 2009-04-15 | Aventis Pharma Inc | Acyl- und sulfonylderivative 6,9- disubstitutierter 2-(trans-1,4-diaminocyclohexyl)-purine und ihre verwendung als antiproliferative mittel |
| GB0117075D0 (en) * | 2000-10-31 | 2001-09-05 | Aventis Pharm Prod Inc | Acyl and sulfonyl derivatives of 6, 9-distributed 2-(trans-1, 4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
| WO2003002565A1 (en) * | 2001-06-27 | 2003-01-09 | Cyclacel Limited | 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
| US6667311B2 (en) | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| US6812232B2 (en) | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
| GB0219052D0 (en) | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| GB0219054D0 (en) | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| EP1591112A4 (en) * | 2003-02-04 | 2006-06-14 | Yakult Honsha Kk | BREAST CANCER RESISTANT PROTEIN INHIBITOR |
| US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
| RU2462246C2 (ru) * | 2006-03-30 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней |
| CN104119336B (zh) * | 2007-10-05 | 2016-08-24 | 维拉斯通股份有限公司 | 嘧啶取代的嘌呤衍生物 |
| CN102241646B (zh) * | 2010-05-14 | 2014-04-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 己烯酮类化合物及其医药用途 |
| WO2013130461A1 (en) | 2012-02-29 | 2013-09-06 | The Scripps Research Institute | Wee1 degradation inhibitors |
| WO2015005491A1 (ja) * | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法 |
| PL3244891T3 (pl) | 2015-01-16 | 2022-12-27 | The General Hospital Corporation | Związki poprawiające splicing mRNA |
| CN107903274A (zh) * | 2017-12-28 | 2018-04-13 | 窦玉玲 | 一种胺类化合物及其在抗肿瘤药物中的应用 |
| WO2021016263A1 (en) * | 2019-07-21 | 2021-01-28 | University Of Virginia Patent Foundation | Cysteine binding compositions and methods of use thereof |
| WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| GB9414208D0 (en) * | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| DE69627195T2 (de) * | 1995-11-01 | 2004-01-29 | Novartis Ag | Purinderivate und verfahren zu ihrer herstellung |
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
-
1999
- 1999-02-18 WO PCT/US1999/003451 patent/WO1999043676A2/en not_active Ceased
- 1999-02-18 BR BR9908325-6A patent/BR9908325A/pt not_active IP Right Cessation
- 1999-02-18 SK SK1291-2000A patent/SK12912000A3/sk unknown
- 1999-02-18 AP APAP/P/2000/001923A patent/AP1258A/en active
- 1999-02-18 KR KR1020007009421A patent/KR100568658B1/ko not_active Expired - Fee Related
- 1999-02-18 DE DE69918062T patent/DE69918062T2/de not_active Expired - Fee Related
- 1999-02-18 NZ NZ506234A patent/NZ506234A/en active IP Right Revival
- 1999-02-18 ES ES99936074T patent/ES2219038T3/es not_active Expired - Lifetime
- 1999-02-18 TR TR2000/02482T patent/TR200002482T2/xx unknown
- 1999-02-18 CZ CZ20003106A patent/CZ291604B6/cs not_active IP Right Cessation
- 1999-02-18 IL IL13804499A patent/IL138044A0/xx active IP Right Grant
- 1999-02-18 HU HU0100931A patent/HUP0100931A3/hu unknown
- 1999-02-18 EP EP99936074A patent/EP1056745B1/en not_active Expired - Lifetime
- 1999-02-18 AU AU32990/99A patent/AU748178B2/en not_active Ceased
- 1999-02-18 CN CN99803395A patent/CN1128149C/zh not_active Expired - Fee Related
- 1999-02-18 PL PL99344021A patent/PL344021A1/xx unknown
- 1999-02-18 EE EEP200000501A patent/EE04315B1/xx not_active IP Right Cessation
- 1999-02-18 JP JP2000533431A patent/JP2002504553A/ja active Pending
- 1999-02-18 RU RU2000124409/04A patent/RU2191777C2/ru active
- 1999-02-18 SI SI9930621T patent/SI1056745T1/xx unknown
- 1999-02-18 DK DK99936074T patent/DK1056745T3/da active
- 1999-02-18 CA CA002320448A patent/CA2320448C/en not_active Expired - Fee Related
- 1999-02-18 AT AT99936074T patent/ATE269332T1/de not_active IP Right Cessation
- 1999-02-18 PT PT99936074T patent/PT1056745E/pt unknown
- 1999-02-18 UA UA2000095500A patent/UA62996C2/uk unknown
- 1999-02-24 TW TW088102781A patent/TW541308B/zh not_active IP Right Cessation
- 1999-02-25 ZA ZA9901548A patent/ZA991548B/xx unknown
- 1999-02-25 AR ARP990100782A patent/AR019822A1/es active IP Right Grant
-
2000
- 2000-08-23 IL IL138044A patent/IL138044A/en not_active IP Right Cessation
- 2000-08-25 OA OA1200000234A patent/OA11480A/en unknown
- 2000-08-25 NO NO20004281A patent/NO20004281L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20004281L (no) | 6,9-disubstituerte 2-[trans-(4-aminocykloheksyl)amino]puriner, farmasoytisk preparat inneholdende disse, og anvendelse derav for fremstilling av et medikament | |
| CA2320474A1 (en) | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines | |
| NO20020391L (no) | 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater | |
| DK1406876T3 (da) | 2-anilinopyrimidinderivater som inhibitorer af cyclinafhængige kinaser | |
| NO20061660L (no) | 2-pyridonderivate som neutrofil elasaeinhibitor og deres anvendelse | |
| NO20045099L (no) | Peptid-derivater omfattende tiazepingruppen for behandling av hyperlipidemiske tilstander | |
| NO20061700L (no) | 2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse | |
| NO20063931L (no) | Nye sammensetninger inneholdende kinolinforbindelser | |
| NO20044599L (no) | 3-amino-tieno[2,3-b]pyridin-2-karboksysyreamid-forbindelser og fremgangsmater for fremstilling og anvendelser av dem | |
| NO20043851L (no) | Derivater av 4-(imidazol-5-yl)-2-(4-sulfoanilino) pyrimidin med CDK inhibitorisk aktivitet | |
| NO20062692L (no) | Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav | |
| NO20063231L (no) | Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer | |
| NO983493L (no) | Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike | |
| JPH0317080A (ja) | 置換ピリドピリミジン誘導体 | |
| UY25519A1 (es) | Procedimiento para preparar antagonista del receptor de vitronectina | |
| NO160297C (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-oksoazetidinderivater | |
| NO982072L (no) | Amidin- og isotioureaderivater som inhibitorer av nitrogenoksydsyntase | |
| NO20023001L (no) | Substituerte piperazinderivater som MTP inhibitorer | |
| NO20026081L (no) | Nye forbindelser | |
| NO20045132L (no) | Benzo(c)kinolizinderivater, deres fremstilling og anvendelse som 5alfa- reduktaseinhibitorer | |
| NO992731D0 (no) | Nye substituerte tetrahydropyridinforbindelser, fremgangsmÕte ved fremstilling av dem og farmas°ytiske sammensetninger derav | |
| TR199902720T2 (xx) | Nitrik oksit sentaz�n�n inhibit�rleri olarak amidin t�revleri. | |
| NO20041761L (no) | Nye hydroksyalkylindolokarbazolforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| NO973341L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for vasodilatorisk behandling eller profylakse | |
| NO20013601L (no) | Nye morfolinobenzamidsalter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |